Peter G. Thomson net worth and biography

Peter Thomson Biography and Net Worth

Peter Thomson joined Fulcrum in 2018, bringing over 15 years of experience in the life sciences industry. Most recently, he was a consultant for three Third Rock Ventures portfolio companies, where he served as interim head of finance. Before that, he served as head of finance at BIND Therapeutics, where he oversaw all finance and accounting activities, developed the corporate valuation for the company and played an integral role in the company’s sale to Pfizer. Prior to BIND, he was senior director of finance at Ovascience and director of finance at Millennium: The Takeda Oncology Company. In addition, he held positions on the finance teams at Boston Scientific Corporation, Infomedics, Inc., and the Hewlett-Packard Company. Peter earned a bachelor’s from Brown University and an MBA from the University of Chicago Booth School of Business.

What is Peter G. Thomson's net worth?: The estimated net worth of Peter G. Thomson is at least $79,437.67 as of May 11th, 2020. Mr. Thomson owns 21,071 shares of Fulcrum Therapeutics stock worth more than $79,438 as of December 4th. This net worth estimate does not reflect any other assets that Mr. Thomson may own. Learn More about Peter G. Thomson's net worth.
How do I contact Peter G. Thomson?: The corporate mailing address for Mr. Thomson and other Fulcrum Therapeutics executives is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. Fulcrum Therapeutics can also be reached via phone at (617) 651-8851 and via email at [email protected]. Learn More on Peter G. Thomson's contact information.
Has Peter G. Thomson been buying or selling shares of Fulcrum Therapeutics?: Peter G. Thomson has not been actively trading shares of Fulcrum Therapeutics within the last three months. Most recently, on Monday, June 28th, Peter G. Thomson bought 2,300 shares of Fulcrum Therapeutics stock. The stock was acquired at an average cost of $9.00 per share, with a total value of $20,700.00. Learn More on Peter G. Thomson's trading history.
Who are Fulcrum Therapeutics' active insiders?: Fulcrum Therapeutics' insider roster includes James Geraghty (Director), Robert Gould (Insider), Christopher Morabito (Insider), Curtis Oltmans (SVP), and Peter Thomson (CEO). Learn More on Fulcrum Therapeutics' active insiders.
Are insiders buying or selling shares of Fulcrum Therapeutics?: During the last year, insiders at the sold shares 2 times. They sold a total of 5,120 shares worth more than $59,071.84. The most recent insider tranaction occured on May, 7th when insider Greg Tourangeau sold 236 shares worth more than $1,831.36. Insiders at Fulcrum Therapeutics own 4.1% of the company. Learn More about insider trades at Fulcrum Therapeutics.
Information on this page was last updated on 5/7/2024.

Peter G. Thomson Insider Trading History at Fulcrum Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/28/2021	Buy	2,300	$9.00	$20,700.00
1/21/2021	Sell	6,607	$14.00	$92,498.00
5/11/2020	Sell	7,500	$16.00	$120,000.00	21,071
2/24/2020	Sell	5,000	$16.83	$84,150.00	30,923
1/23/2020	Sell	5,000	$17.22	$86,100.00	33,833

Peter G. Thomson Buying and Selling Activity at Fulcrum Therapeutics

Fulcrum Therapeutics Company Overview

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $3.77

$3.58

$3.88

50 Day Range

MA: $3.47

$2.97

$4.00

2 Week Range

Now: $3.77

$2.86

$13.70

Volume

721,973 shs

Average Volume

985,120 shs

Market Capitalization

$203.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.14

The 2024 TECH RESET

From InvestorPlace | Ad

Are we on the edge of the biggest ‘TECH RESET’ in decades?

Click here for the step-by-step details